跳至主要内容
临床试验/NCT01822353
NCT01822353已完成不适用

The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk and Nut Allergy in Adults

Helsinki University Central Hospital2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
23
试验地点
2
主要终点
Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy

研究概览

简要总结

In Finland, the estimated prevalence of physician-diagnosed food allergy in 1-4 year old children is 9%, and the most common allergen is milk. The overall food allergy has been reported to be 3.7%. Hen's egg allergy is among the most common food allergies in childhood. In addition, it predicts later development of allergic disease such as asthma. Most of the egg and milk allergy is transient and disappears in childhood. Currently, the standard of care for food allergy includes strict allergen avoidance. However, oral immunotherapy has been under investigation in children milk, egg, and wheat allergy. Previously, induction of clinical egg tolerance has been reported with egg oral immunotherapy in children aged from 3 to 13 years. In adults, strict avoidance is still the standard care but there is also growing interest in treatment of severe food allergy with oral immunotherapy or anti-IgE.

The investigators aim to analyse the results of per oral immunotherapy treatment in severe IgE-mediated egg, milk, and nut allergy in adults.

Could severe egg, milk and nut allergy be treated with oral immunotherapy treatment in stead of total allergen avoidance and could desensitization thus be achieved?

详细描述

Up to 100 subjects are studied. All subjects are adults having no other severe chronic diseases. The subjects belong to four different groups:

  1. 30 18-50 year olds who start per oral immunotherapy treatment in severe egg allergy.
  2. 30 18-50 year olds who start per oral immunotherapy treatment in severe milk allergy.
  3. 30 18-50 year olds who start per oral immunotherapy treatment in severe nut allergy.
  4. 10 milk allergic 18-50 year olds that have been treated as pilot patients with milk hyposensitisation treatment.

The diagnosis of milk or egg allergy is verified with positive history, skin prick test, egg, milk and nut allergen specific IgE antibodies. In addition, food allergy is verified with an allergen specific challenge test.

Atopic subjects may have simultaneously other allergies. Intermittent mild asthma, and mild and moderate persistent asthma are tolerated and treatment with inhaled steroids and other asthma medication is allowed. Atopic subjects may have additional skin symptoms. Quality of life, anxiety and patient history data is collected by questionnaires. All patients undergo a spirometry with a bronchodilatation test, fractional exhaled nitric oxide and a methacholine challenge before and a year after oral immunotherapy. Those with test results diagnostic for asthma are treated with asthma medication before hyposensitisation treatment is started.

Exclusion criteria: adults with instable cerebrovascular or heart disease, active autoimmune disease or cancer, or use of betablocker agents. In addition, poorly controlled asthma or FEV1 < 70% are not tolerated.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • severe IgE-mediated milk allergy or
  • severe IgE-mediated egg allergy or
  • severe IgE-mediated nut allergy or
  • 18-50 years

排除标准

  • instable cerebrovascular or heart disease
  • active autoimmune disease or cancer
  • use of betablocker agents
  • poorly controlled asthma
  • FEV1 < 70% of the predicted

结局指标

主要结局

Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy

时间窗: One year

Number of the patients that achieve higher tolerance of allergen with immunotherapy in one year than the measured baseline allergen challenge shows.

次要结局

  • Does the Oral Immunotherapy Have en Effect on Airway Inflammation?(One year)
  • Effect of Therapy on Lung Function.(One year)
  • Does Oral Immunotherapy Change Bronchial Hyperreactivity?(One year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Paula Kauppi, MD, PhD

MD, PhD

Helsinki University Central Hospital

研究点 (2)

Loading locations...

相似试验

The Effect of Per Oral Immunotherapy in Severe IgE... | 临床试验